



Clinical Guidance

Paediatric Critical Care: Metabolic Disorders

Summary

This guideline is for staff regarding the management of inborn errors of metabolism. It discusses treatment, differential diagnosis as well as addressing CVVH and necessary investigations when caring for these children.

Document Detail						
Document type	Clinical Guideline					
Document name	Paediatric Critical Care: Metabolic Disorders					
Document location	GTi Clinical Guidance Database					
Version	V3.0					
Effective from	14 th June 2023					
Review date	14 th June 2026					
Owner	Head of Service, PICU					
Author(s)	Jennie Lambert (PICU Consultant) Roshni Vara (Metabolic consultant)					
Approved by, date	Paediatric Clinical Guidelines Committee, June 2023					
Superseded documents	Paediatric Critical Care: Metabolic Disorders V2.0					
Related documents	Metabolic Drug Infusion Guide Neonatal Collapse					
Keywords	Evelina, Child, Paediatric, Intensive care, STRS, Retrieval, Paediatric critical care, Inborn errors, Metabolism, PICU, Metabolic, Hypoglycaemia, Lactate, Ammonia, CVVH					

This clinical guideline has been produced by the South Thames Retrieval Service (STRS) at Evelina London for nurses, doctors and ambulance staff to refer to in the emergency care of critically ill children.

This guideline represents the views of STRS and was produced after careful consideration of available evidence in conjunction with clinical expertise and experience. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient.

Change History						
Date	Change details, since approval	Approved by				
June 2023	Formatting and clarity-e.g aminoacidaemia group removed and organic acidaemia term now used throughout. Glucose replaced dextrose	PCGC				

Paediatric Critical Care

Metabolic Disorders



A rare and heterogenous group of inherited conditions, typically presenting in infants/younger children but can present at any age. If clinical suspicion is high, contact tertiary metabolic team for specialist advice. If patient is clinically unstable, refer to STRS urgently.

Evelina Metabolic team: 0207 188 7188, bleep 1460 STRS: 0207 188 5000

Useful resources: Vademecum Metabolicum (EVM)

British Inherited Metabolic Diseases Group

Clinical features

- Variable -often non-specific
- May be acute or chronic/progressive

Neonates

- Poor feeding/vomiting
- Hypotonia (or hypertonia)
- Jaundice
- · Encephalopathy/seizures
- Dysmorphic features

Infants/older children

- Developmental delay/regression
- Recurrent unexplained vomiting
- Encephalopathy/seizures
- Poor growth/fussy eater
- Acute renal/liver failure
- · Cardiomyopathy
- · Unexplained neurological abnormalities
- Decompensation with intercurrent illness

Acute management

- Manage ABC
- Treat Seizures
- · Monitor for cerebral oedema
- · Early referral to STRS
- Early referral to metabolic team
- · Stop feeds
- · Correct electrolyte/ acid-base disturbances
- Cover for sepsis broad spectrum antibiotic as per local policy
- · Urgent transfer to tertiary centre

Glucose

- Target blood sugar 4-8 mmol/L
- Start 0.9% sodium chloride/10% glucose 2mL/kg/hr – titrate as needed to blood sugar – monitor at least hourly
- Target glucose requirement:
 - Neonates 8-10mg/kg/min
 - Older children 6-8mg/kg/min
- Glucose calculation:

glucose mg/kg/min = glucose% x mL/hrweight x 6

High index of suspicion

- Consanguineous parents
- Previous SIDS/Multiple miscarriages
- · Maternal illness in pregnancy e.g. HELLP, acute fatty liver
- Increased fetal movements (hiccups, seizures)

Differential diagnoses:

- Neonatal collapse
- sepsis, cardiac
- Septic shock
- Infective encephalitis

Mechanism of decompensation

Disorders of intoxication

Often a symptom-free period prior to clinical signs of intoxication

- Urea cycle defects (eg Ornithine transcarbamoylase/OTC deficiency, citrullinemia)
- Organic acidaemias (eg. maple syrup urine disease, methylmalonic acidaemia, propionic acidaemia, glutaric aciduria type 1)
- Carbohydrate disorder (eg. galactosaemia, hereditary fructose intolerance)

• Disorders of energy metabolism

Often present if delay in fuel provision or increased metabolic demand (illness)

- Fatty acid oxidation defects (eg. MCAD, VLCAD, LCHAD)
- Carbohydrate metabolism (eg, Glycogen storage diseases,heriditary fructose 1,6 bisphosphatase deficiency)
- Ketolysis defects
- Mitochondrial disorders

• Disorders of complex molecules

- Lysosomal storage disorders
- Peroxisomal disorders (e.g. adrenoleukodystrophy, peroxisomal biogenesis disorders)
- Congenital disorders of glycosylation

First line metabolic investigations:

- Blood gas lactate, blood sugar, anion gap
- Baseline bloods FBC, U&E, LFT, CK, INR
- Serum save
- Ammonia (correct bottle send on ice)
- Ketones (urine & blood)

Special investigations:

- Blood spot acyl-carnitine profile
 - Plasma amino acids
- Urine ketones, organic acids
- CSF lactate, glucose, glycine, amino acids
- Echo/ECG signs cardiomyopathy?
- EEG seizure disorder? Encephalopathy?
- CT or MRI brain basal ganglia changes?
- Ophthalmology oil-drop cataracts, cherryred spot, retinopathy

Useful screening tests prior to death:

1) Biopsies:

- Muscle one flash frozen sample, one saline gauze sample
- · Liver two samples, flash frozen -80°C
- Skin fibroblasts one sample into viral culture medium (pink fluid kept in PICU fridge at ELCH) OR saline. Store in fridge not freezer.

2) Sample saves:

- Serum save lithium heparin
- Blood for chromosome/DNA store lithium heparin and EDTA
- · Blood spot card
- Urine for organic acid spectrometry

Metabolic disorder type	рН	Anion gap	Lactate	Glucose	Ketones	Ammonia
Urea cycle defects	N or ↑	N	N or ↑	N	N	↑ ↑
Organic acidaemia	1	1	1	N, ↓ or ↑	1	1
Fatty acid oxidation defects	N or ↓	Variable	N or ↑	N or ↓	↓ or N r	N or ↑
Carbohydrate metabolism	N or ↓	N or ↑	1	1	N or ↑	N
Mitochondrial disorders	N or ↓	N or ↑	$\uparrow \uparrow$	N or ↓	N or ↑	N or ↑

Definitive treatment:

- Clear toxic metabolites and prevent ongoing production
- 2. Promote anabolism with glucose as directed by metabolic team
- 3. Supplement cofactors as indicated e.g. biotin, pyridoxine, folate

Disease specific treatments:

1) Neonatal hyperammonaemia

- Renal replacement therapy
- Stop protein Sodium benzoate Sodium phenylbutyrate L-arginine
 Carglumic acid
- Glucose infusion +/ intralipid

2) Organic acidaemia

Stop protein intake. Glucose infusion ± insulin • L-carnitine • Carglumic acid

3) Fatty acid oxidation disorders

Avoid prolonged fast. Glucose infusion NO LIPID

4) Mitochondrial disorders – use 5% glucose and 0.9% sodium chloride

Principles of CVVH

(continuous veno-venous haemofiltration):

- Clear toxic metabolites:
- Ammonia in BCOA/UCD
- Leucine in MSUD
- Instigate CVVH ASAP to prevent irrevocable brain damage:
- Ammonia: > 350 for more than 4 hr
- Leucine: If elevated and encephalopathic.

of infant and logistics but is not as effective

 NB: rapid fall of metabolites may be associated with increasing cerebral oedema
 Peritoneal dialysis may be used due to size

References:

British Inherited Metabolic diseases website: <u>BIMDG</u> <u>webpage</u>

Vademecum Metabolicum website: EVM webpage